These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. Kashiwagi A; Maegawa H J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390 [TBL] [Abstract][Full Text] [Related]
24. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related]
25. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Lapuerta P; Zambrowicz B; Strumph P; Sands A Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134 [TBL] [Abstract][Full Text] [Related]
26. [Euglycemic ketoacidosis : a complication of SGLT2 inhibitors]. Mizuno A; Lolachi S; Pernet A Rev Med Suisse; 2017 May; 13(565):1164-1167. PubMed ID: 28639760 [TBL] [Abstract][Full Text] [Related]
27. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Min SH; Yoon JH; Hahn S; Cho YM Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214 [TBL] [Abstract][Full Text] [Related]
28. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Cariou B; Charbonnel B Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423 [TBL] [Abstract][Full Text] [Related]
29. Hemodynamic and renal implications of sodium-glucose cotransporter- 2 inhibitors in type 2 diabetes mellitus. Tejedor Jorge A Med Clin (Barc); 2016 Nov; 147 Suppl 1():35-43. PubMed ID: 28760224 [TBL] [Abstract][Full Text] [Related]
30. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Ribola FA; Cançado FB; Schoueri JH; De Toni VF; Medeiros VH; Feder D Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):199-211. PubMed ID: 28121337 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis. Zhang L; Zhang M; Lv Q; Tong N Diabetes Res Clin Pract; 2018 Jun; 140():295-303. PubMed ID: 29649541 [TBL] [Abstract][Full Text] [Related]
32. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Scheen AJ Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910 [TBL] [Abstract][Full Text] [Related]
33. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Vallon V; Thomson SC Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313 [TBL] [Abstract][Full Text] [Related]